Other
Combating Illicit Xylazine Act
This bill classifies xylazine—a veterinary sedative increasingly found in illicit street drugs—as a Schedule III controlled substance under federal law. It allows law enforcement to track the drug's distribution and penalize illegal sales, trafficking, and possession. At the same time, the bill protects legitimate veterinary, agricultural, and wildlife uses, ensuring licensed professionals and animal owners can still obtain and administer the sedative without extra registration hurdles.
People affected—not determinable from the text provided
Fiscal magnitude—no CBO estimate published
Reach58provisional · pending reviewrigor: heuristic llm
What this bill touches.
Sentencing & corrections−25Drugs & enforcement−35
Who it helps · who it burdens.
Who it helps
- Existing xylazine manufacturersAre exempt from having to make capital expenditures for Schedule III physical security upgrades at existing facilities, receive expedited processing of transition applications from FDA and DEA, and receive a one-year grace period before Schedule III labeling and packaging rules take effect.
- Veterinarians and animal-care practitionersReceive a 60-day delay on practitioner registration, inventory, and recordkeeping rules, and are permitted to continue lawful veterinary practice while their registration applications are under review.
- Animal owners, caretakers, and authorized animal-control and wildlife programsAre categorized as ultimate users and exempted from Controlled Substances Act registration requirements to possess xylazine lawfully obtained from a registered veterinarian or pharmacy.
Who it burdens
- Xylazine manufacturers and distributorsMust comply with Schedule III regulations, including reporting transactions through the federal ARCOS tracking system, following Schedule III labeling and distribution rules after one year, and completing manufacturer transition applications.
- Veterinarians and practitioners administering xylazineMust comply with Schedule III registration, inventory, and recordkeeping requirements within 60 days of enactment.
- Drug Enforcement Administration and Food and Drug AdministrationMust expedite manufacturer regulatory applications, complete and publicly post a 30-day scientific and law enforcement evaluation, and prepare Congressional reports on xylazine diversion, prevalence, and analogue abuse risks at 18 months and four years.
Who opposes it
- Illicit xylazine traffickers and unauthorized distributorsFace federal Schedule III criminal penalties and potentially enhanced federal sentencing guidelines for illicit manufacturing, distribution, importation, or trafficking of xylazine.